Variant is a biotechnology company committed to accelerating the clinical translation of gene-based therapies for rare inherited retinal diseases (IRDs). Our mission is to generate robust proof-of-concept data that enables the pharmaceutical industry to move confidently toward the development of curative solutions for visual disorders with high unmet need.
We specialize in the use of retinal transcription factors—master regulators that drive the early development of photoreceptors—to reignite cone and rod differentiation in degenerating retinas. This strategy opens new therapeutic avenues, particularly for dominant and recessive forms of IRDs that remain untreatable today.
Variant's platform has demonstrated promising results in preclinical models of orphan retinal diseases, including Leber Congenital Amaurosis (LCA), cone-rod dystrophies, and retinitis pigmentosa.